This market research report from Technavio segments the global myelodysplastic syndrome (MDS) market by class of drugs (alkylating agents, cytotoxic antibiotics, topoisomerase inhibitors, and others), by route of administration (oral and parenteral), and by geography (APAC, EMEA, and the Americas). Leading vendors analysed in this market study are Celgene, Novartis, and Otsuka.
Technavio’s market research analysts estimate the global myelodysplastic syndrome market to grow at a CAGR of around 10% between 2015 and 2019. The Americas is expected to dominate the global market for MDS during the forecast period. Factors like the presence of unmet medical needs in the US coupled with the rise in ageing population in this region are expected to account for this region’s high market domination during the forecast period.
The new market research report from Technavio provides a breakdown and analysis of the myelodysplastic syndrome segments by technology.
“The presence of adequate diagnostic tools and procedures is propelling this market’s growth. Diagnosis techniques like blood count, peripheral blood smear test, microscopic exams, cytochemistry, flow cytometry and immunotherapy, cytogenetics, FISH, and PCR help in the detection of MDS. Such tools are expected to have a positive impact on the usage of drugs for people suffering from MDS,” says Imran Mushtaq, Lead Analyst, Healthcare, Technavio Research.
Physicians prefer parenteral route of administration in drug delivery, owing to its stringent adherence to aseptic procedures. Parenteral drugs are absorbed very quickly and ensure speedier action. These drugs are administered through intravenous, subcutaneous, intrathecal, or intramuscular routes. Vidaza and Dacogen are administerd through parenteral route to the MDS patients.
The key vendors in the global MDS market include Celgene, Novartis, and Otsuka. This market is envisaged to grow at a moderate pace due to the high-unmet medical needs of patients, growing public awareness, and the increase in the ageing patient population. Companies that have the ability to manufacture and market drugs that can effectively treat and cure MDS will gain prominence in this market during the forecast period.
A more detailed analysis is available in the Technavio report, Global Myelodysplastic Syndrome Market 2015-2019.
https://www.technavio.com/%3Cp%3E%3Cstrong%3EWe%20can%20customize%20repor…
